梅尼埃病干预结局的伞状综述
鼓室内注射庆大霉素眩晕控制率最高(89%),但存在轻度听力下降风险及23%主观听力下降率。结论指出多数证据质量低,需个体化症状驱动治疗及高质量试验。
要点
- 鼓室内庆大霉素眩晕控制率89%,但23%患者主观听力下降。
- 鼓室内类固醇获益有限但听力风险较低;正压治疗结果不一。
- 内淋巴囊减压初期眩晕控制75%-82%,但随时间下降。
核心结论
- 鼓室内庆大霉素眩晕控制最强但证据质量低且听力损失风险高。
- 保守治疗如鼓室内类固醇和倍他司汀获益有限且证据混杂。
- 手术与装置干预效果不一,需个体化症状驱动治疗及高质量试验。
研究设计与样本
- 检索CINAHL、Cochrane、PubMed、Scopus,遵循PRISMA 2020与PRISMA-S及Cochrane手册。
- 四名研究者提取数据,可行时采用随机效应模型合并数据。
主要发现
- 鼓室内庆大霉素眩晕控制率最高达89%,伴轻度听力损失风险及23%主观听力下降率。
- 鼓室内类固醇获益有限且听觉风险较少;正压治疗结果不一。
- 针刺作为辅助治疗与其他疗法联用显示症状获益。
- 内淋巴囊减压初期眩晕控制75%-82%,但随时间下降。
- 人工耳蜗改善重度听力损失患者的言语感知和耳鸣。
关键数值与推荐
- 眩晕控制率:鼓室内庆大霉素89%,内淋巴囊减压初期75%-82%。
- 主观听力下降率:鼓室内庆大霉素23%。
- 无合格Meta分析评估抗病毒药、通气管、前庭神经切断或迷路切除术。
临床怎么用
- 鼓室内庆大霉素可用于难治性眩晕但需权衡听力损失风险。
- 鼓室内类固醇和倍他司汀可作为听力风险较低的保守选择。
- 手术与装置干预应基于个体化症状驱动决策。
局限性
- 多数干预证据质量低,结论需谨慎解读。
- 部分干预(抗病毒药、通气管、前庭神经切断、迷路切除术)缺乏合格Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess and summarize the outcomes of major pharmacologic, device-based, and surgical interventions reported in systematic reviews and meta-analyses for the treatment of Meniere's disease. DATA SOURCES: CINAHL, Cochrane, PubMed, Scopus. REVIEW METHODS: Twenty-two systematic reviews with meta-analyses of randomized and nonrandomized studies were identified, assessing interventions including gentamicin, corticosteroids, betahistine, positive pressure therapy, adjunctive acupuncture, endolymphatic sac decompression, and cochlear implantation. The review was reported in accordance with PRISMA 2020 and PRISMA-S, and methods followed Cochrane Handbook guidance. Four investigators extracted data. When possible, data were pooled using a random-effects model. Outcomes included vertigo control, tinnitus improvement, and adverse events. RESULTS: Intratympanic gentamicin showed the highest vertigo control rate (89%) but carried a mild hearing loss risk and a 23% subjective hearing reduction rate. Intratympanic steroids offered modest benefit with fewer auditory risks. Positive pressure therapy showed mixed results, while acupuncture demonstrated symptomatic benefit when combined with other therapies. Endolymphatic sac decompression achieved 75%-82% control of vertigo initially but declined over time. Cochlear implants improved speech perception and tinnitus in profound hearing loss. No eligible meta-analyses evaluated antivirals, ventilation tubes, vestibular nerve section, or labyrinthectomy. CONCLUSION: Intratympanic gentamicin provides the strongest vertigo control but is backed by low-quality evidence and risks hearing loss. Conservative treatments like intratympanic steroids and betahistine show modest benefit with mixed evidence. Adjunctive options like acupuncture require cautious interpretation due to low-quality evidence. Surgical and device-based options demonstrate variable effectiveness, highlighting the need for individualized, symptom-driven care and further high-quality trials.
引用
- Chun WB, Nguyen SA, Mills JF, et al. Intervention Outcomes for Meniere's Disease: An Umbrella Review. Laryngoscope. 2026. PMID: 42420191. doi:10.1002/lary.70736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。